Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

Research studies have shown a strong association between cancer and blood clots in the veins (also known as deep vein thrombosis). These blood clots can flow to the lungs (pulmonary embolism) which in severe cases may be life threatening. Studies have demonstrated that increases in microparticles may contribute to the development of deep vein thrombosis in cancer patients. The purpose of this research study is to see if rosuvastatin lowers the number of tissue factor bearing microparticles in the blood (TFMP). TFMP are small particles that are generated from different types of blood cells in the body. In people who have cancer, TFMP are thought to be generated from cancer cells and may represent a risk factor for deep vein thrombosis.

Key facts

Study ID

NCT01299038

Run by

Beth Israel Deaconess Medical Center

People needed

20

Starts

2010-10-01

Expected to finish

2013-12-01

Last updated by the study team

2020-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic adenocarcinoma of the breast (Stage IV)
• Actively receiving endocrine therapy for at least 6 weeks (with or without HER2 therapy)
• Minimum age 18 years
• ECOG Performance status of 0, 1 or 2
• Normal organ and marrow function as defined in the protocol

You may not qualify if…

• Participants may not be receiving any other study agents
• Actively receiving chemotherapy (exclusive of hormonal or HER2 therapy ) within last 5 weeks
• Any statin therapy within the last 3 weeks
• Asian decent (including Filipino, Chinese, Japanese, Korean, Vietnamese or Asian-Indian origin)
• Concomitant use of the following drugs: cyclosporine, fibrates, niacin, gemfibrozil, ketaconazole, spironolactone, cimetidine, warfarin, erythromycin, or protease inhibitors
• Conditions predisposing to renal failure secondary to rhabdomyolysis
• Recent history of heavy alcohol use as judged by the treating physician
• Known to be pregnant (testing not required) or nursing
• History of rhabdomyolysis on statin therapy
• Known history of Hepatitis C or active hepatitis B infection (baseline testing not required)
• Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, hepatitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Where it is running

• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.